NFKB1 and myocardial infarction: Drugs targeting key pathways such as NF-κB and JAK/STAT can effectively inhibit M1 macrophage activation and encourage its conversion to M2 macrophages, thereby enhancing the immune response and repair processes following myocardial infarction.